Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2017

Summary

Human Papillomavirus Protein E7 (E7) pipeline Target constitutes close to 38 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2017, outlays comprehensive information on the Human Papillomavirus Protein E7 (E7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human Papillomavirus Protein E7 (E7) - Human Papilloma Virus (HPV) E7 protein belongs to a group of proteins called oncoproteins. It plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle. E7 protein has both transforming and trans-activating activities. It induces the disassembly of the E2F1 transcription factor from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Ii interferes with host histone deacetylation mediated by HDAC1 and HDAC2, leading to transcription activation. It plays an important role in the inhibition of both antiviral and antiproliferative functions of host inteferon alpha.  The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 3, 13, 1 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Anal Cancer, Oropharyngeal Cancer, Hepatocellular Carcinoma, Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Non-Small Cell Lung Carcinoma, Rectal Cancer and Recurrent Head And Neck Cancer Squamous Cell Carcinoma. 

Furthermore, this report also reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7)
- The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Human Papillomavirus Protein E7 (E7) - Overview 9
Human Papillomavirus Protein E7 (E7) - Therapeutics Development 10
Products under Development by Stage of Development 10
Products under Development by Therapy Area 11
Products under Development by Indication 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 19
Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment 21
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development 26
Abion Inc 26
Advaxis Inc 26
Bioleaders Corp 27
BioNTech AG 27
Cancer Research Technology Ltd 28
Etubics Corp 28
Formune SL 29
Genexine Inc 29
Hookipa Biotech AG 30
iBio Inc 30
Immunovaccine Inc 31
Inovio Pharmaceuticals Inc 31
MedImmune LLC 32
Selecta Biosciences Inc 32
Transgene SA 33
VLPbio 33
Human Papillomavirus Protein E7 (E7) - Drug Profiles 34
ABN-301 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
axalimogene filolisbac - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
axalimogene filolisbac second generation - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
BLSILSB-710c - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
BVAC-C - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
CerviVax - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
CUE-101 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
CUE-201 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
DPXE-7 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
EDA-HPVE7 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
ETBX-041 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
GLBL-101c - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
GX-188E - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
HB-201 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
human papillomavirus [Serotype 16] vaccine - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
human papillomavirus [serotypes 16] vaccine - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
human papillomavirus vaccine - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
INO-3106 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
MEDI-0457 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
PVX-01 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Recombinant Vector Vaccine to Target Human Papillomavirus Protein E7 for HPV Associated Cervical Cancer - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
SEL-701 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
TA-CIN - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
TG-4001 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Tricurin - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
TTFC-E7SH - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
VGX-3100 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
Vvax-001 - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Human Papillomavirus Protein E7 (E7) - Dormant Products 101
Human Papillomavirus Protein E7 (E7) - Discontinued Products 103
Human Papillomavirus Protein E7 (E7) - Product Development Milestones 104
Featured News & Press Releases 104
Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders 104
Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 104
Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer 105
Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer 106
May 18, 2017: Advaxis to Host Investor & Analyst Day on June 12 107
May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer 107
Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers 108
Apr 18, 2017: Immunovaccine Announces Dosing of First Patient in Investigator-Sponsored Phase 1b/2 Clinical Trial Evaluating Immuno-Oncology Candidate Targeting Incurable HPV-Related Cancers 108
Mar 27, 2017: Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac 109
Mar 23, 2017: EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer 110
Mar 22, 2017: Cue Biopharma Announces Selection of Lead Candidate Cue-101 Targeting Human Papillomavirus -Associated Cancers 110
Mar 15, 2017: Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO's Annual Meeting on Women's Cancer 110
Mar 06, 2017: Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech 112
Feb 06, 2017: Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer 112
Jan 30, 2017: GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology's Annual Meeting on Women's Cancer 113
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 115
Disclaimer 116

List of Tables

Number of Products under Development by Stage of Development, H2 2017 10
Number of Products under Development by Therapy Areas, H2 2017 11
Number of Products under Development by Indication, H2 2017 12
Number of Products under Development by Companies, H2 2017 13
Number of Products under Development by Companies, H2 2017 (Contd..1) 14
Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18
Number of Products under Investigation by Universities/Institutes, H2 2017 19
Products under Investigation by Universities/Institutes, H2 2017 20
Number of Products by Stage and Mechanism of Actions, H2 2017 21
Number of Products by Stage and Route of Administration, H2 2017 23
Number of Products by Stage and Molecule Type, H2 2017 25
Pipeline by Abion Inc, H2 2017 26
Pipeline by Advaxis Inc, H2 2017 26
Pipeline by Bioleaders Corp, H2 2017 27
Pipeline by BioNTech AG, H2 2017 27
Pipeline by Cancer Research Technology Ltd, H2 2017 28
Pipeline by Etubics Corp, H2 2017 28
Pipeline by Formune SL, H2 2017 29
Pipeline by Genexine Inc, H2 2017 29
Pipeline by Hookipa Biotech AG, H2 2017 30
Pipeline by iBio Inc, H2 2017 30
Pipeline by Immunovaccine Inc, H2 2017 31
Pipeline by Inovio Pharmaceuticals Inc, H2 2017 31
Pipeline by MedImmune LLC, H2 2017 32
Pipeline by Selecta Biosciences Inc, H2 2017 32
Pipeline by Transgene SA, H2 2017 33
Pipeline by VLPbio, H2 2017 33
Dormant Products, H2 2017 101
Dormant Products, H2 2017 (Contd..1), H2 2017 102
Discontinued Products, H2 2017 103